Actively Recruiting
Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction
Led by Karolinska Institutet · Updated on 2025-07-01
212
Participants Needed
16
Research Sites
168 weeks
Total Duration
On this page
Sponsors
K
Karolinska Institutet
Lead Sponsor
K
Karolinska Trial Alliance
Collaborating Sponsor
AI-Summary
What this Trial Is About
The optimal anticoagulant for the treatment of left ventricular (LV) thrombus following acute myocardial infarction (AMI) is unclear. The aim of this multicenter randomized study is to evaluate the efficacy of apixaban versus warfarin with respect to thrombus resolution in patients with LV thrombus after AMI.
CONDITIONS
Official Title
Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older at the time of signing the informed consent
- Confirmed left ventricular thrombus by transthoracic echocardiography within 1 to 28 days after acute myocardial infarction
- Signed informed consent to participate
- Women of childbearing potential must have a negative pregnancy test, not be breastfeeding, and agree to use effective contraception
- Women not of childbearing potential must be at least 1 year post-menopausal
You will not qualify if you...
- Current anticoagulant treatment for mechanical heart valve prosthesis, atrial fibrillation (with or without significant mitral valve stenosis), venous thromboembolism, thrombophilia, or preexisting LV thrombus treated with anticoagulants
- High bleeding risk including active non-trivial bleeding, chronic bleeding disorders, severe anemia (hemoglobin less than 80 g/L), or thrombocytopenia (platelet count less than 80 x 10^9)
- Significant liver disease or hepatic insufficiency classified as Child-Pugh C or D
- Allergy, intolerance, or hypersensitivity to apixaban or warfarin
- Contraindications to anticoagulant use according to local labeling
- Participation in other studies on anticoagulant treatment
- Current alcohol or drug abuse
- Any other condition that the investigator judges would make participation unsafe or with life expectancy less than 6 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 16 locations
1
Falu lasarett
Falun, Sweden
Not Yet Recruiting
2
Sahlgrenska University hospital, Mölndal
Gothenburg, Sweden
Not Yet Recruiting
3
Sahlgrenska University hospital, Östra
Gothenburg, Sweden
Not Yet Recruiting
4
Sahlgrenska University hospital
Gothenburg, Sweden
Not Yet Recruiting
5
Linköping University hospital
Linköping, Sweden
Not Yet Recruiting
6
Skånes Universitetssjukhus Lund
Lund, Sweden
Actively Recruiting
7
Skånes University hospital, Malmö
Malmö, Sweden
Not Yet Recruiting
8
Vrinnevi hospital
Nörrköping, Sweden
Not Yet Recruiting
9
Örebro University hospital
Örebro, Sweden
Not Yet Recruiting
10
Karolinska Insitutet
Stockholm, Sweden, 17177
Actively Recruiting
11
Danderyds hospital
Stockholm, Sweden
Not Yet Recruiting
12
Karolinska Univerity Hospital
Stockholm, Sweden
Actively Recruiting
13
Sankt Görans Hospital
Stockholm, Sweden
Not Yet Recruiting
14
Södersjukhuset
Stockholm, Sweden
Not Yet Recruiting
15
Uppsala Akademiska hospital
Uppsala, Sweden
Not Yet Recruiting
16
Västmanlands hospital, Västerås
Västerås, Sweden
Not Yet Recruiting
Research Team
E
Eva Olofsson
CONTACT
S
Stina Smetana
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here